Helm G A, Robertson M W, Jallo G I, Simmons N, Bennett J P
Department of Neurological Surgery, University of Virginia School of Medicine, Charlottesville 22908.
Exp Neurol. 1991 Feb;111(2):181-9. doi: 10.1016/0014-4886(91)90005-w.
Stereotactic implantation of fetal brain regional anlage into adult host brain ("brain transplantation") appears to be an increasingly viable strategy for therapy of neurodegenerative diseases. We have studied implantation of fetal striatum into adult striatum, previously lesioned by neurotoxic amino acid injection, as a model for transplantation therapy of Huntington's disease. The beginning of behavioral recovery to apomorphine is not apparent until 6.5 months after implantation. By 4 months after implantation cerebral blood flow through the implants appears equal to that in the intact contralateral striatum. At this time, cerebral glucose utilization is reduced in the implants but increases following apomorphine treatment. The development of D1 and D2 dopamine (DA) receptors is markedly deficient in the striatal grafts at both 4 and 6.5 months after implantation. Very little D2 radioligand binding was observed in the grafts at either time point; D1 receptors appeared in a patchy fashion by 6.5 months at densities approaching normal striatum. In situ hybridization of D2 dopamine receptor mRNA demonstrated robust hybridization signal in normal striatum and accumbens but no signal in 6.5-month-old striatal grafts. Adenylate cyclase (AC) activity, examined with high-affinity [3H]forskolin binding, also appeared in patches similar to D1 receptors at 6.5 months. In contrast, protein kinase C activity, labeled with [3H]phorbol ester, was very apparent in the grafts at both time points. Higher and generally homogenous densities of muscarinic cholinergic receptors, assessed with [3H]QNB binding, develop in the grafts, but there appear to be few functioning cholinergic terminals, as measured by [3H]hemicholinium binding.(ABSTRACT TRUNCATED AT 250 WORDS)
将胎儿脑区原基立体定向植入成年宿主脑内(“脑移植”)似乎正逐渐成为治疗神经退行性疾病的可行策略。我们研究了将胎儿纹状体植入先前经神经毒性氨基酸注射损伤的成年纹状体,以此作为亨廷顿病移植治疗的模型。直到植入后6.5个月,对阿扑吗啡的行为恢复才开始显现。植入后4个月,通过植入物的脑血流量似乎与完整对侧纹状体的血流量相等。此时,植入物中的脑葡萄糖利用率降低,但在阿扑吗啡治疗后增加。在植入后4个月和6.5个月时,纹状体移植物中D1和D2多巴胺(DA)受体的发育明显不足。在这两个时间点,移植物中均未观察到很少的D2放射性配体结合;到6.5个月时,D1受体以斑片状出现,密度接近正常纹状体。D2多巴胺受体mRNA的原位杂交显示在正常纹状体和伏隔核中有强烈的杂交信号,但在6.5个月大的纹状体移植物中没有信号。用高亲和力的[3H]福司可林结合检测的腺苷酸环化酶(AC)活性在6.5个月时也以类似于D1受体的斑片状出现。相比之下,用[3H]佛波酯标记的蛋白激酶C活性在两个时间点的移植物中都非常明显。用[3H]QNB结合评估,毒蕈碱胆碱能受体在移植物中形成更高且通常均匀的密度,但通过[3H]半胆碱结合测量,似乎几乎没有起作用的胆碱能终末。(摘要截短于250字)